Key Highlights

• FDA Accepts Supplemental Applications: Applications for Amondys 45 and Vyondys 53 were accepted, setting a PDUFA target date of February 28, 2027.

• Seeking Traditional Approval Conversion: The filings aim to convert both exon-skipping therapies from accelerated to traditional approval status.

• Supported by ESSENCE Confirmatory Data: Real-world evidence and confirmatory study data support the de-risking step for Sarepta's DMD franchise.

Sarepta Therapeutics (NASDAQ: SRPT) surged after the FDA accepted supplemental New Drug Applications for two of its Duchenne muscular dystrophy (DMD) treatments — Amondys 45 (casimersen) and Vyondys 53 (golodirsen) — setting a PDUFA target action date of February 28, 2027.

The filings seek to convert both exon-skipping therapies from accelerated to traditional approval, a significant regulatory milestone that would provide greater long-term certainty for the commercial viability of both treatments within Sarepta's DMD portfolio.

The applications are supported by data from the ESSENCE confirmatory study and real-world evidence, providing the clinical foundation needed to support the conversion from accelerated to traditional FDA approval status.

This represents a meaningful de-risking step for Sarepta's DMD franchise as it navigates ongoing scrutiny around its flagship gene therapy Elevidys, which has faced its own regulatory and safety-related challenges in recent periods.

By securing FDA acceptance for the conversion of these established exon-skipping therapies, Sarepta is reinforcing the durability of a key segment of its commercial portfolio even as attention remains focused on the more complex regulatory dynamics surrounding its gene therapy pipeline.

()